Our 3D Heart Organoids display unique complexities, showing structures such as myocardium, epicardium, coronary vasculature, and sympathetic innervation, which increase its predictive value. These cardiac organoids can be applied for disease modeling (e.g. adult cardiomyopathies, congenital heart diseases & other), target validation & drug efficacy and cardiotoxicity tests.​

Our 2.5D and 3D Kidney organoids show a unique cell-type complexity (e.g. podocytes, proximal tube, distal tube) bringing an added value for disease modeling (e.g. acute kidney injury, chronic kidney disease or others upon request), target validation, and tests for drug efficacy and kidney toxicity.​

We develop 2D & 3D Brain organoids for different brain regions (dorsal and ventral forebrain, midbrain and cerebellum) and its integration into assembloids.​
These models are suitable for brain disease modeling, target validation, drug penetration assays and efficacy/safety tests.

Molecular modeling allows the simulation, and analysis of the structure and behavior of biological molecules at the atomic level. In drug discovery, it plays a key role in predicting how drugs interact with their targets, optimizing lead compounds, and studying molecular mechanisms of action. By enabling detailed visualization and simulation—such as molecular docking, dynamics, and structure refinement—molecular modeling helps researchers explore binding affinities, conformational changes, and physicochemical properties, thereby accelerating the rational design of new therapeutics.​

This approach leverages in silico methods to identify novel protein targets and design or optimize proteins with desired properties for therapeutic applications. Using tools such as sequence alignment, structural modeling, molecular dynamics, and machine learning, our researchers can predict protein function, stability, and interactions. These approaches enable the rational design of protein variants with improved activity, specificity, or pharmacokinetics, accelerating the development of biologics and enhancing our understanding of protein roles in disease mechanisms.​

Bioinformatics allows the analysis integration, and visualization of heterogeneous sets of biological data—such as genomic, proteomic, and chemical information—to identify and validate potential drug targets. By leveraging computational tools, bioinformatics supports tasks like target identification, biomarker discovery, and virtual screening, ultimately streamlining the drug development process and enabling more precise and cost-effective therapeutic strategies.​

We provide analytical support for Transcriptomics & Single-cell RNA-seq, relevant for clinical applications in biomarkers discovery, patients' stratification and prognostic panels development. We provide reproducible results presented in a form of intuitive and interactive reports with publication-ready figures and tables with the key findings.​

Based in our Associate Universidade de Coimbra (reference lab and alfa tester for Sciex, APCAR ISO 9001 Certified) our mass spectrometry platform allows for labelled and label free (ID/Quant) peptide identification, quantification and analysis of postranslational modifications. We also provide in-depth data analysis services to extract relevant data for drug and biomarker discovery.​

In our Associate Universidade de Coimbra, we apply high-resolution LC-MS/MS-based approaches to profile and quantify metabolites across various biological matrices. To enhance metabolite identification, we are currently developing an in-house MS² spectral library, including an expanding set of 300 metabolites.​